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Epigenetic control of an oncogenic microRNA, miR-155, by 
BRCA1
Suhwan Chang and Shyam K. Sharan
Since  its  identification  in  1994,  BRCA1 (Breast 
Cancer 1) has been established as a familial early onset 
breast and ovarian cancer susceptibility gene [1]. The 
protein encoded by this gene is involved in diverse cellular 
processes such as DNA damage repair, cell cycle control, 
ubiquitination  and  transcriptional  regulation  of  target 
genes [2]. Recently, we uncovered a new function of 
BRCA1, adding another mechanism of tumor suppression 
by this multifunctional protein [3]. 
Using a mouse embryonic stem (mES) cell based 
assay [4], we examined the functional consequences of a 
BRCA1 variant, R1699Q, found in some cancer patients.   
One of the functional readouts of this assay is the ability of 
BRCA1 variants to rescue the lethality of Brca1 null mES 
cells.  We found R1699Q to result in a 10-fold reduction in 
survival these ES cells compared to WT human BRCA1. 
Interestingly, we found R1699Q to have no effect on DNA 
damage repair or cell cycle regulation, which are regarded 
as  major  functions  of  BRCA1.  Instead,  microRNA 
expression analysis in embryoid bodies generated from 
WT and R1699Q expressing ES cells, showed that some 
microRNAs  were  differentially  regulated  in  R1699Q 
mutant cells. Discovered in 1993, microRNAs are short 
cellular RNAs (22nt in average) present in eukaryotic cells 
and are regarded as important regulators of diverse cellular 
functions [5]. Generally, microRNAs interact with 3’UTR 
of target mRNAs by complementary sequence matching 
and consequently, repress the translation or induce the 
degradation of target mRNA.
Among  the  candidate  microRNAs  identified,  we 
focused on miR-155 because it showed the highest and 
most consistent increase in the R1699Q mutant cells. 
miR-155  is  a  well-known  oncogenic  microRNA  that 
is encoded by a non-coding RNA BIC (B-cell Insertion 
Cluster). A viral insertion on this gene was shown to 
induce lymphoma. In addition, B-cell specific expression 
of miR-155 in mouse caused B-cell lymphoma [6]. Based 
on  these  findings,  we  hypothesized  that  the  possible 
repression of an oncogenic microRNA by BRCA1 may 
be a novel mode of tumor suppression. Indeed, a series 
of experiments supported this idea and we found that 
BRCA1  recruits  HDAC2  complex  to  the  miR-155 
promoter.   Consequently, the promoter is epigenetically 
silenced  through  the  deacetylation  of  H2A  and  H3 
histones.  More importantly, our study also showed the 
up-regulation of miR-155 in BRCA1 deficient or BRCA1 
mutant human tumors. Finally, based on our observation 
that the knockdown of miR-155 in a Brca1 mutant tumor 
cell line attenuates in vivo tumor growth, we proposed a 
therapeutic potential of anti-miR-155 agent for BRCA1-
associated breast cancer. 
Even  though  we  have  described  the  mechanism 
of BRCA1-mediated silencing of miR-155 promoter in 
detail, there are several issues that need to be resolved 
to  fully  understand  the  complex  mechanism  of  the 
BRCA1 mediated microRNA regulation and its effect 
on the breast cancer. First, what is the role of miR-155 
in BRCA1-meidated tumorigenesis?  Because a single 
microRNA is predicted to regulate up to 200 mRNAs [7], 
it is important to identify the targets of miR-155 in breast 
epithelial cells that contribute to tumorigenesis.  Second, 
what other microRNAs are epigenetically regulated by 
BRCA1? Identification of these other microRNAs and 
their targets will be a key step towards understanding 
the BRCA1 regulated microRNA network and its role in 
tumorigenesis. 
Interestingly,  we  found  that  the  knockdown  of 
BRCA1 results in a 2 to 3-fold increase in miR-155 levels.   
In contrast, we observed 50 to 150-fold increase in miR-
155 in human breast cancer cell lines or tumor samples 
suggesting that this increase may not be caused only by 
BRCA1 loss.  We hypothesize that other transcription 
factors may activate the miR-155 promoter after it is 
epigenetically  activated  due  to  the  loss  of  BRCA1. 
Identification  of  such  regulatory  factors  will  help  us 
to  fully  understand  the  regulations  of  this  oncogenic 
microRNA during the tumorigenesis. One of the possible 
regulatory factors is TGFβ , which has been shown to 
induce miR-155 expression via SMAD4 [8].  Finally, 
as a cautionary note, it is worth mentioning that anti-
miR-155 agents need to be carefully tested in vivo for 
their therapeutic effects.  Functional studies using miR-
155 knockout mice have shown that miR-155 is essential 
for normal immune function [9]. Considering the systemic 
inhibition of miR-155 will abrogate the immune function 
that  can  be  advantageous  for  the  tumor  growth,  anti-
miR-155 agents may have to be delivered directly to the 
tumor cells.  
In  summary,  while  our  finding  that  BRCA1 
epigenetically silences an oncogenic microRNA is quite 
significant, many questions remain to be answered. We 
hope that our efforts to answer these questions will lead 
to a better understanding of the tumor suppressor function 
of BRCA1 and allow us to develop novel therapeutic Oncotarget 2012; 3:  5 - 6 6 www.impactjournals.com/oncotarget
strategies for the breast cancer.
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